1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Amyotrophic Lateral Sclerosis ALS: new trials by email Literature Review of Amyotrophic Lateral Sclerosis ALS trials Research Report on Amyotrophic Lateral Sclerosis ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS β-hydroxy-β-methylbutyrate (HMB) - Amyotrophic Lateral Sclerosis ALS | Phase 1 | Not yet recruiting | Duke University | 100 | 2026-10-01 | 2026-09-08 |
| Intestinal Microbiome Transplant in ALS MTP-101C - Amyotrophic Lateral Sclerosis ALS | Phase 1 / Phase 2 | Recruiting | Duke University | 20 | 2026-01-27 | 2026-07-08 |
| Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis RJK002 Intrathecal injection - Amyotrophic Lateral Sclerosis Als | Phase 1 | Active not recruiting | RJK Biopharma Ltd | 9 | 2024-09-24 | 2025-11-20 |
| ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments Astaxanthin, Protandim, Melatonin - Amyotrophic Lateral Sclerosis ALS | Phase 2 | Completed | Duke University | 50 | 2024-06-12 | 2026-10-27 |
Amyotrophic Lateral Sclerosis (4)
Central Nervous System Diseases (4) · Metabolic Diseases (4) · Motor Neuron Disease (4) · Nervous System Diseases (4) · Neurodegenerative Diseases (4) · Neuromuscular Diseases (4) · Nutritional and Metabolic Diseases (4) · Proteostasis Deficiencies (4) · Spinal Cord Diseases (4) · TDP-43 Proteinopathies (4)
Melatonin (1) · Protandim (1) · astaxanthine (1) · mitoquinone (1)
Duke University (3) · RJK Biopharma Ltd (1)
United States (3) · China (1)
Richard Bedlack, MD, PhD (2) · Dongsheng Fan, PhD (1)